Abstract 180P
Background
Along with the prolonged survival of cancer patients in recent years comes another dilemma, multiple primary cancers (MPC), which rob cancer patients of their privilege to optimal treatments. Nonetheless, understanding the hereditary and postnatal predisposition of MPC is still in its infancy.
Methods
We included 47,550 cancer patients in UK Biobank. Hazardous and protective HLA alleles concerning MPC were recognized leveraging stepwise logistic regression, which was further validated by log-rank test and Cox proportional hazard model. Logistic regression was used to investigate the organ-specific association between HLA and MPC. Cox proportional hazard model was used to explore potential interventions.
Results
Two protective (DPA1*02:02 and DRB1*04:03) and four hazardous (A*26:01, A*24:03, DPB1*20:01 and DQB1*06:01) HLA alleles are significantly associated with MPC risk for male, whereas one protective (DRB5*01:01) and four hazardous (A*03:02, DRB1*08:03, DQB1*05:04, and DPB1*11:01) for female. Compared with patients without MPC-related HLA alleles, both male and female patients carrying protective HLA alleles have lower risk of MPC (HR, 0.67 [95% CI, 0.53-0.83] and HR, 0.84 [95% CI, 0.73-0.97], respectively), while those carrying hazardous HLA alleles have higher risk of MPC (HR, 1.31 [95% CI, 1.09-1.57] and HR, 1.55 [95% CI, 1.25-1.93], respectively). HLA alleles are associated with organ-specific MPC occurrence. Lower animal fat intake subsided (HR, 0.46 [95% CI, 0.26-0.82]) while unqualified vegetable fat intake increased MPC risk (HR, 2.23 [95% CI, 1.22-4.07]) for male cancer patients carrying hazardous HLA alleles. Lower free sugar intake subsided the risk of MPC for female patients carrying hazardous HLA alleles (HR, 0.34 [95% CI, 0.15-0.74]).
Conclusions
HLA alleles might help to understand the predisposition and organ-specific incidence of MPC. Intervention on diet could counteract the risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongyi Dong.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
165P - Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): A sub analysis of PHERGain trial
Presenter: Maria Gion Cortes
Session: Poster session 01
166P - Metabolomic prediction of breast cancer treatment toxicities
Presenter: Max Piffoux
Session: Poster session 01
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Presenter: Tan Yujing
Session: Poster session 01
168P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: SHRUTI KAHOL
Session: Poster session 01
169P - Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Presenter: Ningning Zhang
Session: Poster session 01
170P - Clinical significance and functional role of GPR56 (ADGRG1) in breast cancer
Presenter: Haizhu Chen
Session: Poster session 01
172P - T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Presenter: Nicha Zungsontiporn
Session: Poster session 01
173P - Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Presenter: Jayant Khandare
Session: Poster session 01
174P - Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Presenter: Maria Pouyiourou
Session: Poster session 01